Comments
Lincoln Pharmaceuticals Ltd (LPL) plans to invest about Rs 90 crore on reconstruction and expansion of its existing plant and also to set up a new plant for the regulated markets.
, which manufactures and markets therapeutic products under the guidelines of World Health Organisation-Good Manufacturing Practices (WHO-GMP), mainly for Indian and semi-regulated markets of Africa, plans to invest about Rs 90 crore on reconstruction and expansion of its existing plant and also to set up a new plant for the regulated markets.
The BSE-listed LPL is scrapping its existing factory altogether at Khatraj in Ahmedabad district this year and expanding the reconstructed plant with capacities enhanced by about 30 times, Mr Mahendra Patel, Managing Director, told Business Line here on Wednesday.
The Khatraj plant set up in 1979, having a capacity to manufacture 10-15 lakh units a month, will be expanded to produce over three crore units a month with an investment of nearly Rs 30 crore. The plant will continue to make injectables, liquid ampoule vials, dry powder injectables, ointments and liquid syrups for the Indian and semi-regulated markets of Africa, South-East Asia and Latin America.
It is expected to be commissioned by December.
Nearly Rs 110 crore of the LPL, out of the turnover of Rs 174 crore last year, came from the Indian and semi-regulated markets.
Other Plans
Besides, LPL is planning to set up a separate plant at Nandasan in Mehsana district with an investment of nearly Rs 60 crore in this financial year. The plant would be built according to the requirements of the regulated markets of the US and Europe and will manufacture solid doses (tablets and capsules), Mr Patel said.
Work on this venue is expected to commence in January-February 2012.
For the new plant, he said, LPL is in talks with an American company for possible manufacturing work outsourced to the Mehsana facility.
LPL's R&D centre, on which it is investing five per cent of profits, has been awarded four patents and 15 more are in the pipeline.
In February, LPL launched a new version of paracetamol for a 12-hour relief from pain. In April, it launched Tinnex injection in India, as part of its agreement with Phafag AG, Switzerland, to produce the Caroverine molecule for treatment of what is commonly known as “ringing in the ear.”
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.